APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pediatric Drugs and Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pediatric Drugs and Vaccines Market Outlook and Growth Opportunities 2026

20 December 2025208 pages

Choose your research edition.

Industry ResearchPediatric Drugs and Vaccines Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pediatric Drugs and Vaccines Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Pediatric Drugs and Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pediatric Drugs and Vaccines Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Pediatric Drugs and Vaccines Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Pediatric Drugs and Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pediatric Drugs and Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pediatric Drugs and Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pediatric Drugs and Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pediatric Drugs and Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pediatric Drugs and Vaccines market include Janssen Biologics B.V. (USA), Takeda, Sanofi S.A (France), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Merck & Co., Inc. (USA), Eli Lilly and Company (USA), Pfizer, Inc. (USA) and GlaxoSmithKline plc. (UK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pediatric Drugs and Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pediatric Drugs and Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pediatric Drugs and Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pediatric Drugs and Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Pediatric Drugs and Vaccines Segment by Company

Janssen Biologics B.V. (USA)

Takeda

Sanofi S.A (France)

Novartis AG (Switzerland)

Novo Nordisk A/S (Denmark)

Merck & Co., Inc. (USA)

Eli Lilly and Company (USA)

Pfizer, Inc. (USA)

GlaxoSmithKline plc. (UK)

Amgen, Inc. (USA)

Shionogi Inc. (USA)

Genentech, Inc. (USA)

F. Hoffmann-La Roche Ltd (Switzerland)

Bristol-Myers Squibb Company (USA)

Boehringer Ingelheim GmbH (Germany)

AstraZeneca Plc. (UK)

Allergan, Inc. (USA)

Actelion Pharmaceuticals

Abbott Laboratories (USA)

Pediatric Drugs and Vaccines Segment by Type

Diphtheria

Pneumococcal Diseases

Hepatitis

Influenza

Mumps

Meningococcal Diseases

Others

Pediatric Drugs and Vaccines Segment by Application

Child

Newborn

Infant

Pediatric Drugs and Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pediatric Drugs and Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pediatric Drugs and Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pediatric Drugs and Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Pediatric Drugs and Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pediatric Drugs and Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pediatric Drugs and Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pediatric Drugs and Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pediatric Drugs and Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pediatric Drugs and Vaccines industry.

Chapter 3: Detailed analysis of Pediatric Drugs and Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pediatric Drugs and Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pediatric Drugs and Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pediatric Drugs and Vaccines Industry Trends Table 2. Pediatric Drugs and Vaccines Industry Drivers Table 3. Pediatric Drugs and Vaccines Industry Opportunities and Challenges Table 4. Pediatric Drugs and Vaccines Industry Restraints Table 5. Global Pediatric Drugs and Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pediatric Drugs and Vaccines Revenue Share by Company (2021-2026) Table 7. Global Pediatric Drugs and Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pediatric Drugs and Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Pediatric Drugs and Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pediatric Drugs and Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pediatric Drugs and Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Pediatric Drugs and Vaccines Company, Product Type & Application Table 13. Global Pediatric Drugs and Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pediatric Drugs and Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diphtheria Table 18. Significant Companies of Pneumococcal Diseases Table 19. Significant Companies of Hepatitis Table 20. Significant Companies of Influenza Table 21. Significant Companies of Mumps Table 22. Significant Companies of Meningococcal Diseases Table 23. Significant Companies of Others Table 24. Global Pediatric Drugs and Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Pediatric Drugs and Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 26. Global Pediatric Drugs and Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 27. Global Pediatric Drugs and Vaccines Sales Volume Share by Type (2021-2026) Table 28. Global Pediatric Drugs and Vaccines Sales Volume Share by Type (2027-2032) Table 29. Global Pediatric Drugs and Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Pediatric Drugs and Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Pediatric Drugs and Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Pediatric Drugs and Vaccines Sales Value Share by Type (2021-2026) Table 33. Global Pediatric Drugs and Vaccines Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Child Table 35. Significant Companies of Newborn Table 36. Significant Companies of Infant Table 37. Global Pediatric Drugs and Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Pediatric Drugs and Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Pediatric Drugs and Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Pediatric Drugs and Vaccines Sales Volume Share by Application (2021-2026) Table 41. Global Pediatric Drugs and Vaccines Sales Volume Share by Application (2027-2032) Table 42. Global Pediatric Drugs and Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Pediatric Drugs and Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Pediatric Drugs and Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Pediatric Drugs and Vaccines Sales Value Share by Application (2021-2026) Table 46. Global Pediatric Drugs and Vaccines Sales Value Share by Application (2027-2032) Table 47. Global Pediatric Drugs and Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Pediatric Drugs and Vaccines Sales by Region (2021-2026) & (K Units) Table 49. Global Pediatric Drugs and Vaccines Sales Market Share by Region (2021-2026) Table 50. Global Pediatric Drugs and Vaccines Sales by Region (2027-2032) & (K Units) Table 51. Global Pediatric Drugs and Vaccines Sales Market Share by Region (2027-2032) Table 52. Global Pediatric Drugs and Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Pediatric Drugs and Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Pediatric Drugs and Vaccines Sales Value Share by Region (2021-2026) Table 55. Global Pediatric Drugs and Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Pediatric Drugs and Vaccines Sales Value Share by Region (2027-2032) Table 57. Global Pediatric Drugs and Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Pediatric Drugs and Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Pediatric Drugs and Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Pediatric Drugs and Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Pediatric Drugs and Vaccines Sales by Country (2021-2026) & (K Units) Table 62. Global Pediatric Drugs and Vaccines Sales Market Share by Country (2021-2026) Table 63. Global Pediatric Drugs and Vaccines Sales by Country (2027-2032) & (K Units) Table 64. Global Pediatric Drugs and Vaccines Sales Market Share by Country (2027-2032) Table 65. Global Pediatric Drugs and Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Pediatric Drugs and Vaccines Sales Value Market Share by Country (2021-2026) Table 67. Global Pediatric Drugs and Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Pediatric Drugs and Vaccines Sales Value Market Share by Country (2027-2032) Table 69. Janssen Biologics B.V. (USA) Company Information Table 70. Janssen Biologics B.V. (USA) Business Overview Table 71. Janssen Biologics B.V. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Janssen Biologics B.V. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 73. Janssen Biologics B.V. (USA) Recent Development Table 74. Takeda Company Information Table 75. Takeda Business Overview Table 76. Takeda Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Takeda Pediatric Drugs and Vaccines Product Portfolio Table 78. Takeda Recent Development Table 79. Sanofi S.A (France) Company Information Table 80. Sanofi S.A (France) Business Overview Table 81. Sanofi S.A (France) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Sanofi S.A (France) Pediatric Drugs and Vaccines Product Portfolio Table 83. Sanofi S.A (France) Recent Development Table 84. Novartis AG (Switzerland) Company Information Table 85. Novartis AG (Switzerland) Business Overview Table 86. Novartis AG (Switzerland) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Novartis AG (Switzerland) Pediatric Drugs and Vaccines Product Portfolio Table 88. Novartis AG (Switzerland) Recent Development Table 89. Novo Nordisk A/S (Denmark) Company Information Table 90. Novo Nordisk A/S (Denmark) Business Overview Table 91. Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Product Portfolio Table 93. Novo Nordisk A/S (Denmark) Recent Development Table 94. Merck & Co., Inc. (USA) Company Information Table 95. Merck & Co., Inc. (USA) Business Overview Table 96. Merck & Co., Inc. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Merck & Co., Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 98. Merck & Co., Inc. (USA) Recent Development Table 99. Eli Lilly and Company (USA) Company Information Table 100. Eli Lilly and Company (USA) Business Overview Table 101. Eli Lilly and Company (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Eli Lilly and Company (USA) Pediatric Drugs and Vaccines Product Portfolio Table 103. Eli Lilly and Company (USA) Recent Development Table 104. Pfizer, Inc. (USA) Company Information Table 105. Pfizer, Inc. (USA) Business Overview Table 106. Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 108. Pfizer, Inc. (USA) Recent Development Table 109. GlaxoSmithKline plc. (UK) Company Information Table 110. GlaxoSmithKline plc. (UK) Business Overview Table 111. GlaxoSmithKline plc. (UK) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline plc. (UK) Pediatric Drugs and Vaccines Product Portfolio Table 113. GlaxoSmithKline plc. (UK) Recent Development Table 114. Amgen, Inc. (USA) Company Information Table 115. Amgen, Inc. (USA) Business Overview Table 116. Amgen, Inc. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Amgen, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 118. Amgen, Inc. (USA) Recent Development Table 119. Shionogi Inc. (USA) Company Information Table 120. Shionogi Inc. (USA) Business Overview Table 121. Shionogi Inc. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Shionogi Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 123. Shionogi Inc. (USA) Recent Development Table 124. Genentech, Inc. (USA) Company Information Table 125. Genentech, Inc. (USA) Business Overview Table 126. Genentech, Inc. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Genentech, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 128. Genentech, Inc. (USA) Recent Development Table 129. F. Hoffmann-La Roche Ltd (Switzerland) Company Information Table 130. F. Hoffmann-La Roche Ltd (Switzerland) Business Overview Table 131. F. Hoffmann-La Roche Ltd (Switzerland) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. F. Hoffmann-La Roche Ltd (Switzerland) Pediatric Drugs and Vaccines Product Portfolio Table 133. F. Hoffmann-La Roche Ltd (Switzerland) Recent Development Table 134. Bristol-Myers Squibb Company (USA) Company Information Table 135. Bristol-Myers Squibb Company (USA) Business Overview Table 136. Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Product Portfolio Table 138. Bristol-Myers Squibb Company (USA) Recent Development Table 139. Boehringer Ingelheim GmbH (Germany) Company Information Table 140. Boehringer Ingelheim GmbH (Germany) Business Overview Table 141. Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Product Portfolio Table 143. Boehringer Ingelheim GmbH (Germany) Recent Development Table 144. AstraZeneca Plc. (UK) Company Information Table 145. AstraZeneca Plc. (UK) Business Overview Table 146. AstraZeneca Plc. (UK) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. AstraZeneca Plc. (UK) Pediatric Drugs and Vaccines Product Portfolio Table 148. AstraZeneca Plc. (UK) Recent Development Table 149. Allergan, Inc. (USA) Company Information Table 150. Allergan, Inc. (USA) Business Overview Table 151. Allergan, Inc. (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Allergan, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio Table 153. Allergan, Inc. (USA) Recent Development Table 154. Actelion Pharmaceuticals Company Information Table 155. Actelion Pharmaceuticals Business Overview Table 156. Actelion Pharmaceuticals Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Actelion Pharmaceuticals Pediatric Drugs and Vaccines Product Portfolio Table 158. Actelion Pharmaceuticals Recent Development Table 159. Abbott Laboratories (USA) Company Information Table 160. Abbott Laboratories (USA) Business Overview Table 161. Abbott Laboratories (USA) Pediatric Drugs and Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Abbott Laboratories (USA) Pediatric Drugs and Vaccines Product Portfolio Table 163. Abbott Laboratories (USA) Recent Development Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Pediatric Drugs and Vaccines Distributors List Table 167. Pediatric Drugs and Vaccines Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Pediatric Drugs and Vaccines Product Image Figure 2. Global Pediatric Drugs and Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pediatric Drugs and Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pediatric Drugs and Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Pediatric Drugs and Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pediatric Drugs and Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diphtheria Image Figure 10. Pneumococcal Diseases Image Figure 11. Hepatitis Image Figure 12. Influenza Image Figure 13. Mumps Image Figure 14. Meningococcal Diseases Image Figure 15. Others Image Figure 16. Global Pediatric Drugs and Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Pediatric Drugs and Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Pediatric Drugs and Vaccines Sales Volume Share by Type (2021-2032) Figure 19. Global Pediatric Drugs and Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Pediatric Drugs and Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Pediatric Drugs and Vaccines Sales Value Share by Type (2021-2032) Figure 22. Child Image Figure 23. Newborn Image Figure 24. Infant Image Figure 25. Global Pediatric Drugs and Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Pediatric Drugs and Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Pediatric Drugs and Vaccines Sales Volume Share by Application (2021-2032) Figure 28. Global Pediatric Drugs and Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Pediatric Drugs and Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Pediatric Drugs and Vaccines Sales Value Share by Application (2021-2032) Figure 31. Global Pediatric Drugs and Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Pediatric Drugs and Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Pediatric Drugs and Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Pediatric Drugs and Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Pediatric Drugs and Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. North America Pediatric Drugs and Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Pediatric Drugs and Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Pediatric Drugs and Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Pediatric Drugs and Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Pediatric Drugs and Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Pediatric Drugs and Vaccines Sales Value (2021-2032) & (US$ Million) Figure 42. South America Pediatric Drugs and Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Pediatric Drugs and Vaccines Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Pediatric Drugs and Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Pediatric Drugs and Vaccines Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Pediatric Drugs and Vaccines Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Diphtheria
  • Pneumococcal Diseases
  • Hepatitis
  • Influenza
  • Mumps
  • Meningococcal Diseases
  • Others
Applications
  • Child
  • Newborn
  • Infant
Companies covered
  • Janssen Biologics B.V. (USA)
  • Takeda
  • Sanofi S.A (France)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Merck & Co., Inc. (USA)
  • Eli Lilly and Company (USA)
  • Pfizer, Inc. (USA)
  • GlaxoSmithKline plc. (UK)
  • Amgen, Inc. (USA)
  • Shionogi Inc. (USA)
  • Genentech, Inc. (USA)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bristol-Myers Squibb Company (USA)
  • Boehringer Ingelheim GmbH (Germany)
  • AstraZeneca Plc. (UK)
  • Allergan, Inc. (USA)
  • Actelion Pharmaceuticals
  • Abbott Laboratories (USA)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pediatric Drugs and Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Pediatric Drugs and Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Pediatric Drugs and Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pediatric Drugs and Vaccines Market Dynamics
  1. 2.1 Pediatric Drugs and Vaccines Industry Trends
  2. 2.2 Pediatric Drugs and Vaccines Industry Drivers
  3. 2.3 Pediatric Drugs and Vaccines Industry Opportunities and Challenges
  4. 2.4 Pediatric Drugs and Vaccines Industry Restraints
3 Pediatric Drugs and Vaccines Market by Company
  1. 3.1 Global Pediatric Drugs and Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Pediatric Drugs and Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Pediatric Drugs and Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Pediatric Drugs and Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Pediatric Drugs and Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Pediatric Drugs and Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Pediatric Drugs and Vaccines Company Product Type and Application
  8. 3.8 Global Pediatric Drugs and Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pediatric Drugs and Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pediatric Drugs and Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pediatric Drugs and Vaccines Market by Type
  1. 4.1 Pediatric Drugs and Vaccines Type Introduction
  2. 4.1.1 Diphtheria
  3. 4.1.2 Pneumococcal Diseases
  4. 4.1.3 Hepatitis
  5. 4.1.4 Influenza
  6. 4.1.5 Mumps
  7. 4.1.6 Meningococcal Diseases
  8. 4.1.7 Others
  9. 4.2 Global Pediatric Drugs and Vaccines Sales Volume by Type
  10. 4.2.1 Global Pediatric Drugs and Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Pediatric Drugs and Vaccines Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Pediatric Drugs and Vaccines Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Pediatric Drugs and Vaccines Sales Value by Type
  14. 4.3.1 Global Pediatric Drugs and Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Pediatric Drugs and Vaccines Sales Value by Type (2021-2032)
  16. 4.3.3 Global Pediatric Drugs and Vaccines Sales Value Share by Type (2021-2032)
5 Pediatric Drugs and Vaccines Market by Application
  1. 5.1 Pediatric Drugs and Vaccines Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Newborn
  4. 5.1.3 Infant
  5. 5.2 Global Pediatric Drugs and Vaccines Sales Volume by Application
  6. 5.2.1 Global Pediatric Drugs and Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pediatric Drugs and Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pediatric Drugs and Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pediatric Drugs and Vaccines Sales Value by Application
  10. 5.3.1 Global Pediatric Drugs and Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pediatric Drugs and Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pediatric Drugs and Vaccines Sales Value Share by Application (2021-2032)
6 Pediatric Drugs and Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Pediatric Drugs and Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pediatric Drugs and Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Pediatric Drugs and Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Pediatric Drugs and Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Pediatric Drugs and Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pediatric Drugs and Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pediatric Drugs and Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pediatric Drugs and Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Pediatric Drugs and Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pediatric Drugs and Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Pediatric Drugs and Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pediatric Drugs and Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Pediatric Drugs and Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pediatric Drugs and Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pediatric Drugs and Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pediatric Drugs and Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Pediatric Drugs and Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pediatric Drugs and Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pediatric Drugs and Vaccines Sales Value Share by Country, 2025 VS 2032
7 Pediatric Drugs and Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Pediatric Drugs and Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pediatric Drugs and Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pediatric Drugs and Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Pediatric Drugs and Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Pediatric Drugs and Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Pediatric Drugs and Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pediatric Drugs and Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pediatric Drugs and Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pediatric Drugs and Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pediatric Drugs and Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pediatric Drugs and Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Biologics B.V. (USA)
  2. 8.1.1 Janssen Biologics B.V. (USA) Company Information
  3. 8.1.2 Janssen Biologics B.V. (USA) Business Overview
  4. 8.1.3 Janssen Biologics B.V. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Biologics B.V. (USA) Pediatric Drugs and Vaccines Product Portfolio
  6. 8.1.5 Janssen Biologics B.V. (USA) Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pediatric Drugs and Vaccines Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Sanofi S.A (France)
  14. 8.3.1 Sanofi S.A (France) Company Information
  15. 8.3.2 Sanofi S.A (France) Business Overview
  16. 8.3.3 Sanofi S.A (France) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi S.A (France) Pediatric Drugs and Vaccines Product Portfolio
  18. 8.3.5 Sanofi S.A (France) Recent Developments
  19. 8.4 Novartis AG (Switzerland)
  20. 8.4.1 Novartis AG (Switzerland) Company Information
  21. 8.4.2 Novartis AG (Switzerland) Business Overview
  22. 8.4.3 Novartis AG (Switzerland) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG (Switzerland) Pediatric Drugs and Vaccines Product Portfolio
  24. 8.4.5 Novartis AG (Switzerland) Recent Developments
  25. 8.5 Novo Nordisk A/S (Denmark)
  26. 8.5.1 Novo Nordisk A/S (Denmark) Company Information
  27. 8.5.2 Novo Nordisk A/S (Denmark) Business Overview
  28. 8.5.3 Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Product Portfolio
  30. 8.5.5 Novo Nordisk A/S (Denmark) Recent Developments
  31. 8.6 Merck & Co., Inc. (USA)
  32. 8.6.1 Merck & Co., Inc. (USA) Company Information
  33. 8.6.2 Merck & Co., Inc. (USA) Business Overview
  34. 8.6.3 Merck & Co., Inc. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co., Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
  36. 8.6.5 Merck & Co., Inc. (USA) Recent Developments
  37. 8.7 Eli Lilly and Company (USA)
  38. 8.7.1 Eli Lilly and Company (USA) Company Information
  39. 8.7.2 Eli Lilly and Company (USA) Business Overview
  40. 8.7.3 Eli Lilly and Company (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly and Company (USA) Pediatric Drugs and Vaccines Product Portfolio
  42. 8.7.5 Eli Lilly and Company (USA) Recent Developments
  43. 8.8 Pfizer, Inc. (USA)
  44. 8.8.1 Pfizer, Inc. (USA) Company Information
  45. 8.8.2 Pfizer, Inc. (USA) Business Overview
  46. 8.8.3 Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
  48. 8.8.5 Pfizer, Inc. (USA) Recent Developments
  49. 8.9 GlaxoSmithKline plc. (UK)
  50. 8.9.1 GlaxoSmithKline plc. (UK) Company Information
  51. 8.9.2 GlaxoSmithKline plc. (UK) Business Overview
  52. 8.9.3 GlaxoSmithKline plc. (UK) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline plc. (UK) Pediatric Drugs and Vaccines Product Portfolio
  54. 8.9.5 GlaxoSmithKline plc. (UK) Recent Developments
  55. 8.10 Amgen, Inc. (USA)
  56. 8.10.1 Amgen, Inc. (USA) Company Information
  57. 8.10.2 Amgen, Inc. (USA) Business Overview
  58. 8.10.3 Amgen, Inc. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Amgen, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
  60. 8.10.5 Amgen, Inc. (USA) Recent Developments
  61. 8.11 Shionogi Inc. (USA)
  62. 8.11.1 Shionogi Inc. (USA) Company Information
  63. 8.11.2 Shionogi Inc. (USA) Business Overview
  64. 8.11.3 Shionogi Inc. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shionogi Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
  66. 8.11.5 Shionogi Inc. (USA) Recent Developments
  67. 8.12 Genentech, Inc. (USA)
  68. 8.12.1 Genentech, Inc. (USA) Company Information
  69. 8.12.2 Genentech, Inc. (USA) Business Overview
  70. 8.12.3 Genentech, Inc. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Genentech, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
  72. 8.12.5 Genentech, Inc. (USA) Recent Developments
  73. 8.13 F. Hoffmann-La Roche Ltd (Switzerland)
  74. 8.13.1 F. Hoffmann-La Roche Ltd (Switzerland) Company Information
  75. 8.13.2 F. Hoffmann-La Roche Ltd (Switzerland) Business Overview
  76. 8.13.3 F. Hoffmann-La Roche Ltd (Switzerland) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 F. Hoffmann-La Roche Ltd (Switzerland) Pediatric Drugs and Vaccines Product Portfolio
  78. 8.13.5 F. Hoffmann-La Roche Ltd (Switzerland) Recent Developments
  79. 8.14 Bristol-Myers Squibb Company (USA)
  80. 8.14.1 Bristol-Myers Squibb Company (USA) Company Information
  81. 8.14.2 Bristol-Myers Squibb Company (USA) Business Overview
  82. 8.14.3 Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb Company (USA) Recent Developments
  85. 8.15 Boehringer Ingelheim GmbH (Germany)
  86. 8.15.1 Boehringer Ingelheim GmbH (Germany) Company Information
  87. 8.15.2 Boehringer Ingelheim GmbH (Germany) Business Overview
  88. 8.15.3 Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Product Portfolio
  90. 8.15.5 Boehringer Ingelheim GmbH (Germany) Recent Developments
  91. 8.16 AstraZeneca Plc. (UK)
  92. 8.16.1 AstraZeneca Plc. (UK) Company Information
  93. 8.16.2 AstraZeneca Plc. (UK) Business Overview
  94. 8.16.3 AstraZeneca Plc. (UK) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Plc. (UK) Pediatric Drugs and Vaccines Product Portfolio
  96. 8.16.5 AstraZeneca Plc. (UK) Recent Developments
  97. 8.17 Allergan, Inc. (USA)
  98. 8.17.1 Allergan, Inc. (USA) Company Information
  99. 8.17.2 Allergan, Inc. (USA) Business Overview
  100. 8.17.3 Allergan, Inc. (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Allergan, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
  102. 8.17.5 Allergan, Inc. (USA) Recent Developments
  103. 8.18 Actelion Pharmaceuticals
  104. 8.18.1 Actelion Pharmaceuticals Company Information
  105. 8.18.2 Actelion Pharmaceuticals Business Overview
  106. 8.18.3 Actelion Pharmaceuticals Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Actelion Pharmaceuticals Pediatric Drugs and Vaccines Product Portfolio
  108. 8.18.5 Actelion Pharmaceuticals Recent Developments
  109. 8.19 Abbott Laboratories (USA)
  110. 8.19.1 Abbott Laboratories (USA) Company Information
  111. 8.19.2 Abbott Laboratories (USA) Business Overview
  112. 8.19.3 Abbott Laboratories (USA) Pediatric Drugs and Vaccines Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Abbott Laboratories (USA) Pediatric Drugs and Vaccines Product Portfolio
  114. 8.19.5 Abbott Laboratories (USA) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pediatric Drugs and Vaccines Value Chain Analysis
  2. 9.1.1 Pediatric Drugs and Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pediatric Drugs and Vaccines Sales Mode & Process
  6. 9.2 Pediatric Drugs and Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pediatric Drugs and Vaccines Distributors
  9. 9.2.3 Pediatric Drugs and Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst